Analysts at StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Get Free Report) in a report issued on Friday. The firm set a “sell” rating on the specialty pharmaceutical ...

Police in Savannah are asking that you avoid the area near the Savannah Mall due to a crash that's shut down several lanes.

Explore why NBIS struggles in the competitive generative AI space, facing cloud giants. Learn about its growth, valuation, ...

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

Would you like to own an iconic part of Detroit’s skyline? One of the towers in the downtown Renaissance Center is now up for ...

Despite a potentially conservative outlook, SentinelOne guided to 23% growth for FY26. Read why investors should use the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

A stock screener is a tool used by traders to identify stocks that match a certain set of criteria. For example, you can use stock scanners like Magnifi and Interactive Brokers to filter stocks by ...

Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener ... with a price target consensus of $23.00. TENX market cap is currently $20.59M and ...

LEVEL-2 is a global Phase 3, double-blind, randomized, placebo-controlled study of oral levosimendan in patients with PH-HFpEF. Patients will be randomized to receive an oral dose of levosimendan (2mg ...

Tenax Therapeutics (TENX) has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is ...